MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaa530

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020

Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.

Rawson Timothy M, Moore Luke S P, Zhu Nina, Ranganathan Nishanthy, Skolimowska Keira, Gilchrist Mark, Satta Giovanni, Cooke Graham, Holmes Alison

СтатьяПоддержка исследования: вне правительства СШАОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND

To explore and describe the current literature surrounding bacterial/fungal coinfection in patients with coronavirus infection.

METHODS

MEDLINE, EMBASE, and Web of Science were searched using broad-based search criteria relating to coronavirus and bacterial coinfection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-CoV-2, and other coronavirus) and bacterial/fungal coinfection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal coinfections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-CoV-2 even in absence of coinfection was performed.

RESULTS

1007 abstracts were identified. Eighteen full texts reporting bacterial/fungal coinfection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140; 61%). Nine of 18 (50%) studies reported on COVID-19, 5/18 (28%) on SARS-1, 1/18 (6%) on MERS, and 3/18 (17%) on other coronaviruses. For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal coinfection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described. For non-COVID-19 cases, bacterial/fungal coinfection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported.

CONCLUSIONS

Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus-associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal coinfection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic is urgently required.

Для цитирования: Rawson Timothy M, Moore Luke S P, Zhu Nina, Ranganathan Nishanthy, Skolimowska Keira, Gilchrist Mark, Satta Giovanni, Cooke Graham, Holmes Alison. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020. DOI: 10.1093/cid/ciaa530.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.